Dr. Guy Rouleau

Dr. Guy Rouleau is AOC Co-Chair, and the Director of the Montreal Neurological Institute at McGill University. He has >900 peer-reviewed articles and has received >$78M in CIHR and other research funding. He has led several multinational research networks and is co-founder of the Tanenbaum Open Science Institute. He was a founder and CEO of a biotech company (RGS Genome Inc) that merged with Xenon Pharmaceuticals in 2000. Xenon is now traded on Nasdaq with a capitalization of $2 billion. He has served on the boards of several biotechnology companies (e.g., ALS Pharma, Acanthas Pharma Inc, Bioaxone) and is a consultant for some venture capital firms. Dr. Rouleau has received the Order of Canada, Order of Quebec, and Gairdner-Wightman Award.

The Accelerating Clinical Trials Consortium is generously supported through multi-year funding from the Canadian Institutes of Health Research’s Clinical Trials Fund, as part of Canada’s Biomanufacturing and Life Sciences Strategy to ensure that Canadians are well served by a national clinical trials network.